BACKGROUND: Surgical myectomy (SM) and Alcohol septal ablation (ASA) are effective therapies for patients with hypertrophic cardiomyopathy who remain symptomatic despite medical therapy. A plethora of data has recently emerged on the long-term outcomes of these procedures. We hence sought to perform an updated meta-analysis comparing both procedures. METHODS: Studies reporting long-term (>3-years) outcomes of SM and/or ASA were included. The primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular mortality, sudden cardiac death (SCD), reintervention, and complications including death, pacemaker implantation, and stroke. RESULTS: Twenty-two ASA cohorts (n = 4213; follow-up = 6.6-years) and 23 SM cohorts (n = 4240; follow-up = 6.8-years) were included. Septal myectomy was associated with higher periprocedural mortality and stroke (2% vs 1.2%, P = 0.009 and 1.5% vs 0.8% P = 0.013, respectively), but ASA was associated with more need of pacemaker (10% vs 5%, P < 0.001). During long-term follow-up, all-cause mortality, cardiovascular mortality, and sudden cardiac death rates were 1.5%, 0.4%, and 0.3% per person-year in the ASA group and 1.1%, 0.5%, and 0.3% per person-year in the SM group (P = 0.21, P = 0.53, P = 0.43), respectively. Repeat septal reduction intervention(s) were more common after ASA (11% vs 1.5%, P < 0.001). CONCLUSION: Compared with SM, ASA is associated with lower periprocedural mortality and stroke but higher rates of pacemaker implantations and reintervention. However, there was no difference between ASA and SM with regards to long-term all-cause mortality, cardiovascular mortality, or SCD.
BACKGROUND: Surgical myectomy (SM) and Alcohol septal ablation (ASA) are effective therapies for patients with hypertrophic cardiomyopathy who remain symptomatic despite medical therapy. A plethora of data has recently emerged on the long-term outcomes of these procedures. We hence sought to perform an updated meta-analysis comparing both procedures. METHODS: Studies reporting long-term (>3-years) outcomes of SM and/or ASA were included. The primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular mortality, sudden cardiac death (SCD), reintervention, and complications including death, pacemaker implantation, and stroke. RESULTS: Twenty-two ASA cohorts (n = 4213; follow-up = 6.6-years) and 23 SM cohorts (n = 4240; follow-up = 6.8-years) were included. Septal myectomy was associated with higher periprocedural mortality and stroke (2% vs 1.2%, P = 0.009 and 1.5% vs 0.8% P = 0.013, respectively), but ASA was associated with more need of pacemaker (10% vs 5%, P < 0.001). During long-term follow-up, all-cause mortality, cardiovascular mortality, and sudden cardiac death rates were 1.5%, 0.4%, and 0.3% per person-year in the ASA group and 1.1%, 0.5%, and 0.3% per person-year in the SM group (P = 0.21, P = 0.53, P = 0.43), respectively. Repeat septal reduction intervention(s) were more common after ASA (11% vs 1.5%, P < 0.001). CONCLUSION: Compared with SM, ASA is associated with lower periprocedural mortality and stroke but higher rates of pacemaker implantations and reintervention. However, there was no difference between ASA and SM with regards to long-term all-cause mortality, cardiovascular mortality, or SCD.
Authors: Richard Collis; Oliver Watkinson; Constantinos O'Mahony; Oliver P Guttmann; Antonis Pantazis; Maria Tome-Esteban; Victor Tsang; Venkatachalam Chandrasekaran; Christopher G A McGregor; Perry M Elliott Journal: Eur J Heart Fail Date: 2017-11-16 Impact factor: 15.534
Authors: Jason Nogic; Youlin Koh; Marek Bak; Robert P Gooley; Ian T Meredith; Liam M McCormick Journal: Heart Lung Circ Date: 2017-10-13 Impact factor: 2.975
Authors: Anna Woo; William G Williams; Richard Choi; E Douglas Wigle; Evelyn Rozenblyum; Katie Fedwick; Samuel Siu; Anthony Ralph-Edwards; Harry Rakowski Journal: Circulation Date: 2005-04-11 Impact factor: 29.690
Authors: Paul Sorajja; Josepha Binder; Rick A Nishimura; David R Holmes; Charanjit S Rihal; Bernard J Gersh; John F Bresnahan; Steve R Ommen Journal: Catheter Cardiovasc Interv Date: 2012-04-17 Impact factor: 2.692
Authors: Iacopo Olivotto; Steve R Ommen; Martin S Maron; Franco Cecchi; Barry J Maron Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: José M de la Torre Hernandez; Monica Masotti Centol; Piedad Lerena Saenz; Ángel Sánchez Recalde; Federico Gimeno de Carlos; Pablo Piñón Esteban; Diego Fernandez Rodriguez; Marta Sitges Carreño; Manel Sabate Tenas; Javier Zueco Gil Journal: Rev Esp Cardiol (Engl Ed) Date: 2013-12-04